Welcome to LookChem.com Sign In|Join Free
  • or
(S)-2-[4,4-bis(trifluoromethyl)-3-(4-(3-(2-methylphenyl)ureido)-3-methoxybenzyl)-2,5-dioxoimidazolidin-1-yl]-2-(cyclopropylmethyl)acetic acid is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

457059-31-3

Post Buying Request

457059-31-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

457059-31-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 457059-31-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,5,7,0,5 and 9 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 457059-31:
(8*4)+(7*5)+(6*7)+(5*0)+(4*5)+(3*9)+(2*3)+(1*1)=163
163 % 10 = 3
So 457059-31-3 is a valid CAS Registry Number.

457059-31-3Relevant academic research and scientific papers

Trifluoromethyl-substituted hydantoins, versatile building blocks for rational drug design

Wehner, Volkmar,Stilz, Hans-Ulrich,Osipov, Sergej N.,Golubev, Alexander S.,Sieler, Joachim,Burger, Klaus

, p. 4295 - 4302 (2007/10/03)

Preparatively simple, one-pot syntheses of trifluoromethyl-substituted hydantoins starting from Boc-protected imines of hexafluoroacetone and trifluoropyruvate are described. They represent valuable building blocks for the construction of constrained pept

Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them

-

, (2008/06/13)

The present invention relates to novel imidazolidine derivatives of formula I, wherein A, E, Z, R1, R2, R3, R4 and R5 have the meanings indicated in the claims. The compounds of formula I are valuable pharmaceutical active compounds which are suitable, for example, for the treatment of inflammatory diseases, including rheumatoid arthritis, or allergic diseases. The compounds of formula I are inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4 belonging to the integrins group. They are generally suitable for the treatment of diseases which are caused by an undesired extent of leukocyte adhesion and/or leukocyte migration or are associated therewith or in which cell-cell or cell-matrix interactions which are based on the interactions of VLA-4 receptors with their ligands play a role. The invention furthermore relates to processes for the preparation of the compounds of formula I, their use and pharmaceutical preparations which contain compounds of formula I.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 457059-31-3